Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With PDRN Versus Fractional CO₂ Laser

Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With Polydeoxyribonucleotide (PDRN) Versus Fractional CO₂ Laser: A Randomized Controlled Clinical Study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07472192

Acronym

PDRN CO2 LASER

Enrollment

Registered

2026-03-16

Start date

2026-03-01

Completion date

2026-07-01

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial Scarring

Brief summary

Facial scars are frequently deemed unpleasant and can profoundly impact a patient's psychological health. This study compares the effectiveness, safety, and capacity to speed up scar healing in the maxillofacial region between fractional carbon dioxide (CO₂) laser therapy alone and polydeoxyribonucleotide (PDRN) combined with CO₂ laser therapy.

Interventions

DRUGPolydeoxyribonucleotide

intralesional PDRN injections

DEVICEFractional CO2 laser assisted PDT

Fractional carbon dioxide (CO₂) laser therapy for facial scars

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Masking Description

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Age Limitations: Participants must be between 18 and 50 years of age. * Recently cut wounds or surgical scars from about (1-6 months). * Consent to Participate: Willingness to provide informed consent and engage in all aspects of the study.

Exclusion criteria

* Pregnancy or breastfeeding at the time of study. * Known allergy to PDRN. * Medication use that could affect wound healing or inflammation, such as: * Isotretinoin. * Anticancer drugs. * High-dose corticosteroids. * Anticoagulants. * Uncontrolled medical diseases (e.g., unstable diabetes, cardiac conditions).

Design outcomes

Primary

Measure	Time frame	Description
Vancouver Scar Scale	4 months	The study used the standard Vancouver Scar Scale, which evaluates four characteristics of scars: Total Score Range: 0 (normal skin) to 13 (severe hypertrophic scar)

Countries

Egypt

Contacts

CONTACTOmnia Tarek Hosni

200048686@must.edu.eg01117196173

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026